| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC4859 | Spla2 Inhibitor Pyr-1 | Novel potent sPLA2 inhibitor, selectively targeting hGIIA and hGIID |
|
| DCC4860 | Spmtrien | Novel isosteric charge-deficient spermine analogue |
|
| DCC4861 | spongiacidin C | USP7 inhibitor from the marine sponge Stylissa massa |
|
| DCC4862 | Spongosine | Pivotal intercellular signal transmitter |
|
| DCC4863 | Spop-in-6lc | Novel SPOP inhibitor, suppressing the viability and inhibiting the colony formation of ccRCC cell lines driven by cytoplasmic SPOP |
|
| DCC4864 | Spt-in-1 | Novel potent serine palmitoyl transferase (SPT) inhibitor |
|
| DCC4865 | Sptssb-binder-18 | Novel potent and selective binder of small subunit B of the serine palmitoyltransferase complex (SPTSSB) |
|
| DCC4866 | Spu-106 | Novel specific PAK4 inhibitor, effectively inhibiting the invasion of SGC7901 cells without cytotoxicity, regulating the PAK4/LIMK1/cofilin and PAK4/SCG10 signaling pathways |
|
| DCC4867 | Sr-01000634273-1 | Novel inhibitor of the in vivo aggregation of |
|
| DCC4868 | Sr10098 | Novel NR4A nuclear receptor modulator |
|
| DCC4869 | Sr10658 | Novel NR4A nuclear receptor modulator |
|
| DCC4870 | Sr142948a | Selective neurotensin antagonist |
|
| DCC4871 | Sr-17398 Hydrochloride | Novel Unc-51-Like Kinase 1 (ULK1) |
|
| DCC4872 | Sr2067 | Novel partial agonist of PPARgamma |
|
| DCC4873 | Sr24237 | Novel NR4A nuclear receptor modulator |
|
| DCC4874 | Sr-3737 | Potent inhibitor of both JNK3 and p38 |
|
| DCC4875 | Sr-4326 | Novel Inhibitor of c-Jun N-terminal Kinase 3 (JNK3) |
|
| DCC4876 | Sr-43845 | Novel renin inhibitor |
|
| DCC4877 | Sr-58611a | The first selective β3 adrenergic agonist, showing to possess a profile of antidepressant activity in rodents |
|
| DCC4878 | Sr8185 | Novel Selective TBK1/IKK dual inhibitor with anticancer potency |
|
| DCC4879 | Srctide | Peptide substrate for many protein kinases, such as Blk, BTK, cKit, EPHA1, EPHB2, EPHB3, ERBB4, FAK, Flt3, IGF-1R, ITK, Lck, MET, MUSK, Ret, Src, TIE2, TrkB, VEGF-R1 (Flt-1) and VEGF-R2 (KDR) |
|
| DCC4880 | Srebp-in-dhg | Novel inhibitor of sterol regulatory element-binding protein (SREBP), impairing the SREBP activity by inhibiting glucose transporters and thereby activating AMP-activated protein kinase (AMPK) |
|
| DCC4881 | Sri-22138 | Novel mixed μ opioid receptor (MOR) agonist and δ/κ opioid receptor (DOR/KOR) antagonist |
|
| DCC4882 | Sri-29132 | Highly blood-brain barrier permeant, potent, and selective for LRRK2 kinase activity, being effective in attenuating pro-inflammatory responses in macrophages and rescuing neurite retraction phenotypes in neurons. |
|
| DCC4883 | Sri-31040 | Potent DAT allosteric modulator, partially inhibiting DAT uptake without altering DAT-mediated reverse transport and with minimal inhibition of DAT binding |
|
| DCC4884 | Sri-35241 | Novel inhibitor of thrombospondin 1 activation of TGF-β, blocking TGF-β activation (pIC50 = 8.12 nM) and has a plasma half life of 1.8 h (iv) |
|
| DCC4885 | Sri-36160 | Novel potent inhibitor of Wn/ß-catenin signaling in cancer cells |
|
| DCC4886 | Sri-37683 | Novel GLUT inhibitor, preferentially inhibiting the growth of GBM cells with minimal toxicity to non-neoplastic astrocytes and neurons, also inhibiting glucose uptake and decrease the glycolytic capacity and glycolytic reserve capacity of GBM patient-deri |
|
| DCC4887 | Sri-37684 | Novel GLUT inhibitor, preferentially inhibiting the growth of GBM cells with minimal toxicity to non-neoplastic astrocytes and neurons, also inhibiting glucose uptake and decrease the glycolytic capacity and glycolytic reserve capacity of GBM patient-deri |
|
| DCC4888 | Sri-39067 | Novel MOR agonist/DOR antagonist that produced systemically active potent antinociceptive activity in tail-flick assay in mice |
|
